Latest News and Updates

* (R) = Regulatory press releases

Oct 21, 2023

(R) Cantargia: ESMO 2023 presentation of nadunolimab phase I clinical interim data in triple-negative breast cancer shows promising efficacy and safety

Oct 16, 2023

Cantargia to present clinical phase Ib data on nadunolimab in triple-negative breast cancer at ESMO Congress 2023

Oct 4, 2023

(R) Cantargia: Third party appeals recent EPO decision to maintain granted Cantargia patent

Sep 29, 2023

Cantargia publishes AACR Special Conference poster on new nadunolimab clinical and biomarker data in pancreatic cancer

Sep 27, 2023

(R) Cantargia presents new clinical data further supporting nadunolimab’s antitumor activity and a key role of its target IL1RAP in pancreatic cancer

Sep 20, 2023

(R) Cantargia: New preclinical data on nadunolimab potential to enhance anti-tumor effect of immunotherapy presented at CRI-ENCI-AACR

Sep 18, 2023

(R) Cantargia announces new nadunolimab clinical trial in leukemia financed by external US grant

Sep 6, 2023

(R) Cantargia: FDA grants Orphan Drug Designation to CAN10 for treatment of systemic sclerosis

Sep 5, 2023

(R) Cantargia expands clinical pipeline and starts treatment in second program, CAN10, for autoimmune diseases

Aug 22, 2023

(R) Cantargia publishes half year report

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

Press releases

(R) Cantargia: ESMO 2023 presentation of nadunolimab phase I clinical interim data in triple-negative breast cancer shows promising efficacy and safety

Cantargia to present clinical phase Ib data on nadunolimab in triple-negative breast cancer at ESMO Congress 2023

(R) Cantargia: Third party appeals recent EPO decision to maintain granted Cantargia patent

Cantargia publishes AACR Special Conference poster on new nadunolimab clinical and biomarker data in pancreatic cancer

(R) Cantargia presents new clinical data further supporting nadunolimab’s antitumor activity and a key role of its target IL1RAP in pancreatic cancer

(R) Cantargia: New preclinical data on nadunolimab potential to enhance anti-tumor effect of immunotherapy presented at CRI-ENCI-AACR

(R) Cantargia announces new nadunolimab clinical trial in leukemia financed by external US grant

(R) Cantargia: FDA grants Orphan Drug Designation to CAN10 for treatment of systemic sclerosis

(R) Cantargia expands clinical pipeline and starts treatment in second program, CAN10, for autoimmune diseases

(R) Cantargia publishes half year report

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Interview with CEO Hilde H. Steineger - 2025-10-07

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye interviews Interim CEO Damian Marron - 2025-02-07